Biohaven Management
Management criteria checks 2/4
Biohaven's CEO is Vlad Coric, appointed in May 2022, has a tenure of 2.33 years. directly owns 3.33% of the company’s shares, worth $161.02M. The average tenure of the management team and the board of directors is 2.1 years and 2 years respectively.
Key information
Vlad Coric
Chief executive officer
US$6.8m
Total compensation
| CEO salary percentage | n/a |
| CEO tenure | 2.3yrs |
| CEO ownership | 3.3% |
| Management average tenure | 2.1yrs |
| Board average tenure | 2yrs |
Recent management updates
Recent updates
Biohaven: Positive SCA Treatment Data Leads To Q4 2024 NDA Submission Catalyst
Sep 23Biohaven: Taldefgrobep Alfa Might Have A Place Beyond SMA Treatment
Jul 26Biohaven: Promising Pipeline With Troriluzole, Taldefgrobep Alfa, And BHV-7000 Leading The Charge
May 18We're Keeping An Eye On Biohaven's (NYSE:BHVN) Cash Burn Rate
Apr 06
Calculating The Intrinsic Value Of Biohaven Ltd. (NYSE:BHVN)
Mar 01Biohaven's Bounce Back: A Missed Call Turns Bullish (Rating Upgrade)
Feb 28Biohaven Ltd.: Too Far, Too Fast (Rating Downgrade)
Dec 08Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Dec 04Biohaven: Soaring Share Price On New Data Could Be Too Good To Be True
Sep 27Biohaven's Valuation Challenge: Weighing Potential Against Setbacks
Aug 28Here's Why We're Watching Biohaven's (NYSE:BHVN) Cash Burn Situation
Jul 22Biohaven: A Promising Investment In Innovative Neurological Therapies
Jun 14Biohaven: Spinout's Rampant Share Price Gains May Be Giving Pfizer A Headache
Jun 06Will Biohaven (NYSE:BHVN) Spend Its Cash Wisely?
Apr 06Biohaven's spinal muscular atrophy therapy gets FDA fast track status
Feb 21Biohaven Ltd: Assessing The Spinoff
Dec 07Biohaven Non-GAAP EPS of -$1.25
Nov 09CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Jun 30 2024 | n/a | n/a | -US$747m |
| Mar 31 2024 | n/a | n/a | -US$517m |
| Dec 31 2023 | US$7m | n/a | -US$408m |
| Sep 30 2023 | n/a | n/a | -US$465m |
| Jun 30 2023 | n/a | n/a | -US$431m |
| Mar 31 2023 | n/a | n/a | -US$544m |
| Dec 31 2022 | US$7m | US$200k | -US$570m |
Compensation vs Market: Vlad's total compensation ($USD6.82M) is about average for companies of similar size in the US market ($USD8.14M).
Compensation vs Earnings: Vlad's compensation has increased whilst the company is unprofitable.
CEO
Vlad Coric (53 yo)
2.3yrs
Tenure
US$6,819,189
Compensation
Dr. Vladimir Coric, M.D., also known as Vlad, is an Independent Director at Revance Therapeutics, Inc. since March 01, 2023. He is Director at Pyramid Biosciences Inc. since August 2020. He had been Indepe...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 2.3yrs | US$6.82m | 3.33% $ 161.0m | |
| Chief Financial Officer | no data | US$2.76m | 0.20% $ 9.8m | |
| Chief Scientific Officer | 2.1yrs | US$2.58m | 0.034% $ 1.7m | |
| Senior Vice President of Clinical Operations | no data | US$2.56m | 0.10% $ 4.9m | |
| Director of Regulatory Affairs & Operations | 1.7yrs | no data | no data | |
| VP & Chief Accounting Officer | no data | no data | no data | |
| Vice President of Investor Relations | no data | no data | no data | |
| General Counsel & Chief Legal Officer | no data | no data | no data | |
| President | no data | no data | no data | |
| Chief Commercial Officer of Rare Diseases | no data | no data | no data | |
| Senior Vice President of Commercial Strategy | no data | no data | no data | |
| Senior Vice President of GHEOR & Epidemiology | no data | no data | no data |
2.1yrs
Average Tenure
57yo
Average Age
Experienced Management: BHVN's management team is considered experienced (2.1 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Chairman & CEO | 2.3yrs | US$6.82m | 3.33% $ 161.0m | |
| Independent Director | 2yrs | US$555.94k | 6.83% $ 330.7m | |
| Independent Director | 2yrs | US$567.94k | 0.027% $ 1.3m | |
| Independent Director | 2yrs | US$562.94k | 0.014% $ 663.4k | |
| Independent Director | 2yrs | US$545.94k | 1.71% $ 82.7m | |
| Lead Independent Director | 2yrs | US$597.94k | 0.016% $ 776.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2yrs | US$542.94k | 0.0027% $ 129.7k | |
| Director | 2yrs | US$535.94k | 0.024% $ 1.2m | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.0yrs
Average Tenure
64yo
Average Age
Experienced Board: BHVN's board of directors are not considered experienced ( 2 years average tenure), which suggests a new board.